Skip to content
Back to Blog
Bio
2026-11-096 min read18

Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

KITIM Consulting Team

What the November 6 Amendment Changes

On November 6, Korea's Ministry of Food and Drug Safety (MFDS) published a proposed amendment to its *Regulation on Fees for Drug Approvals*, along with a proposed amendment to the *Enforcement Rule of the Advanced Regenerative Bio Act* covering advanced biologics. According to press reports, product approval fees would rise as follows:

  • Advanced biologics and new biologics: KRW 8.03 million → KRW 20.71 million (about 2.6x)
  • Data-submission drugs: KRW 2.6 million → KRW 16.04 million (about 6.2x)
  • Comment deadlines: November 26 for the administrative notice and December 16 for the legislative notice
  • This is a separate change from the new drug approval fee increase announced in 2024 (about KRW 410 million). That increase was aimed mainly at new synthetic drugs. This one covers biologics and data-submission drugs. Because the proposal has not been finalized, check the final notice for the effective date and any transition rules.

    Why the Increase: Making Fees Match Review Costs

    Since the 2024 increase, MFDS has kept moving fees closer to what reviews actually cost. The stated goals are to add reviewers, fund expedited review, and discourage "test the waters" filings submitted before the dossier is ready.

    The press has reported concern that smaller pharma companies, many of whose filings are data-submission drugs, will be hit hardest. The question to watch is whether the higher fees lead to better service, such as shorter review times and more pre-submission consultations.

    Start by Identifying Your Product Type

    Product categories

  • Data-submission drugs: improved products with a new composition, strength, dosage form or route of administration.
  • New biologics and advanced biologics: cell and gene therapies, tissue-engineered products, and similar products.
  • Estimating the cost impact (illustrative)

    Each data-submission drug filing would cost about KRW 13.44 million more. If you plan three such filings next year, fees alone rise by about KRW 40.32 million. Each new biologic filing would cost about KRW 12.68 million more.

    To see whether other fees, such as those for variations or clinical trial approvals, are also changing, check the fee tables in the full text of the proposal.

    Should You File Earlier?

    The key question is whether filings received before the effective date will pay the old fee, which depends on the transition rules. Until those rules are confirmed, we do not recommend rushing every filing forward.

  • A rushed, incomplete dossier can lead to deficiency requests or rejection.
  • A review delay of several months can cost more than the fee difference.
  • A realistic approach is to bring forward only the dossiers that are already close to ready.
  • Build the higher fees into your 2027 approval roadmap and business plan budgets now.
  • Reducing the Burden With Fee Reductions and Government Support

  • The current regulation includes fee reductions for SMEs and for domestically developed products. Check the full text of the proposal to see whether these provisions stay the same.
  • Fee reductions require documents such as an SME confirmation certificate, so make sure yours will still be valid when you file.
  • If you are running a government-funded bio R&D project, check your grant agreement and the program's management guidelines to see whether regulatory fees count as an eligible project cost.
  • Make Your Comments Count

    You can submit comments to MFDS directly or through an industry association by the deadlines (November 26 and December 16). Strong comments include:

  • Requests for broader SME fee reductions, a phased increase, or a grace period before the new fees apply
  • Specific cost figures based on your filing plans (for example, three filings in 2027 adding KRW 40.32 million)
  • Comments backed by numbers are more likely to influence policy than general complaints about the burden.

    Prepare With KITIM

    The Korea Institute of Technology Innovation Management (KITIM) can estimate the fee impact for each of your products, rework your approval timeline, review whether you qualify for fee reductions, and plan your costs around government support programs. To see how the fee changes affect your approval strategy, contact KITIM for a consultation.

    MFDS Approval FeeAdvanced BiopharmaceuticalsNew BiologicsData-Submission DrugsFee Regulation AmendmentSME Fee ReductionMarketing Authorization BudgetPublic Comment

    Related Posts

    Bio

    Korea's Incremental Modified Drug Criteria Revised After Four Years — MFDS Guideline Updated Oct 30, 2026 (Container Improvement Removed, Broader Non-PK Evidence, No Recognition for Simple Salt Changes): Development Planning and Evidence Design for Pharma SMEs Moving Beyond Generics

    MFDS revised its incremental modified drug recognition guideline on October 30, 2026, for the first time in four years: container improvement is gone, simple salt changes are explicitly excluded, and evidence beyond PK data can now count. This guide shows pharma SMEs how to reassess ongoing projects and design their evidence.

    2026-11-09
    ESG

    A Green Certification Is Just Paper Unless You Use It — A 2026 Guide for Climate-Tech SMEs on Choosing Between Green Technology Certification, Green Product Confirmation and Green Specialized Company Confirmation, and Using Them for Procurement, Guarantees and R&D, Amid the Revised Operating Rules and Criticism of Unverified Reduction Effects

    This guide covers the revised green certification rules and recent criticism over unverified emissions reductions. It also explains how climate-tech SMEs can choose among the three green certifications and use them for procurement, guarantees and R&D.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.